New Drug Evaluations are concise, structured reviews of new drugs recently launched within the NHS. These documents seek to provide a brief overview of the efficacy, safety and cost of new drugs. The primary audiences are primary care healthcare professionals in Northern and Yorkshire such as General Practitioners, Prescribing Advisers, Community/Primary Care Pharmacists and Nurse Prescribers. They are also found to be useful by hospital practitioners and Drug and Therapeutics Committees.
New Drug Evaluations should be read in conjunction with the relevant Summary of Product Characteristics (SPC) and the BNF. Due to the time limited nature of New Drug Evaluations they are published with the expectation that they will not be routinely scheduled for review (see process manual). In view of the continued emergence of new evidence, readers are recommended to re-check the biomedical literature after 18 months beyond the publication date of each NDE (indicated in red).
Agents which have been reviewed by the National Institute for Health and Clinical Excellence (NICE) are indicated by the presence of a (N) after the drug name. Please refer to the NICE website to access guidance for these agents.
This information is produced for use by NHS healthcare professionals. See site disclaimer.
NICE has accredited the process used by the Regional Drug and Therapeutics Centre to produce New Drug Evaluations. Accreditation is valid for 5 years from
7 March 2017.
For more information visit www.nice.org/accreditation
New documents are restricted to stakeholders only for a period of 3 months following publication:
Aug 2019 NDE No. 164 Insulin glargine plus lixisenatide (Suliqua®) for the treatment of T2DM